Hansoh patents new dopamine D1/5 receptor partial agonists
AI Briefing
- • Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. report new dopamine D1/5 receptor partial agonists.
- • These agonists are reportedly useful for treating various conditions including schizophrenia, ADHD, and Parkinson’s disease.
- • New agonists may also be effective for treating sleep disorders, pain, and autism spectrum disorder.
Context
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have reported new dopamine D1 and/or D5 receptor partial agonists. These compounds are said to be useful for treating various conditions.
These new partial agonists may offer treatment options for several diseases, including schizophrenia, ADHD, and Alzheimer's disease, among others.
Advertisement